†CGM sold separately
The t:slim X2™ insulin pump with Control-IQ™ technology can be used as a stand alone pump, or can be integrated with the Dexcom G7 or G6 continuous glucose monitoring (CGM)† system to activate the predictive insulin delivery technology.
The Control‑IQ advanced hybrid closed-loop technology makes it easier by using Dexcom CGM values to predict glucose levels 30 minutes ahead and automatically adjusts basal insulin every 5 minutes, to help increase time in range.1
NEW Tandem t:slim mobile app* coming soon in May 2025
Give yourself the freedom to more easily manage your diabetes with the Tandem t:slim mobile app*
Freedom to bolus
Bolus from your compatible smartphone*,^ without touching your t:slim X2 insulin pump.
Freedom to be discreet
View pump data on your smartphone as a secondary display for your t:slim X2 insulin pump.
Freedom to be in the know
Automatically upload your pump data to the new Tandem Source platform.††
^ Smart device sold separately.
The t:slim X2 insulin pumps, consumables and Dexcom CGM systems are fully funded by Pharmac for New Zealanders with type 1 diabetes under special authority criteria - prescription may be charged**
To determine if this pump is suitable for you, please consult your healthcare professional. For integration with Dexcom G7, you need to upgrade to the t:slim X2 insulin pump with Control-IQ technology (version 7.7 or later), as the Basal-IQ technology is compatible with Dexcom G6.
After starting with the t:slim X2 insulin pump with Basal-IQ, you can update to Control-IQ technology once you have completed the Control-IQ training module and submitted the Control-IQ update form.
Why choose Tandem?
Working with you 24/7 to help you live more freely
- Simplify your routine with zero fingerpricks‡ and no multiple daily injections.
- Experience more than 90% time in range overnight.#,2
- Discreet, modern and simple to learn.
- Freedom to bolus from your smartphone* without touching your pump.
- 97% said it’s easy to use.3
Worry less about your diabetes
- Automatically predicts and helps prevent highs and lows.§
Now powered by Dexcom’s most accurare||,4 sensor
- Dexcom G7†
- To learn more about Dexcom G7, visit Dexcom.com.
Control-IQTM Technology
Predicting glucose levels 30 minutes ahead and suspending insulin, to help reduce the frequency and duration of lows.1,¶
Dexcom G7 CGM Integration
Compatible with Dexcom G7 CGM requiring zero fingerpricks.‡
Updateable Platform
Capable of remote feature updates, instead of waiting for a whole new pump!
Large, Colour Touchscreen
The t:slim X2 insulin pump was designed to be user-friendly, with an easy-to-read, easy-to-use interface.
Interested in Control-IQ Technology?
Fill in the form below and one of our representatives will be in touch regarding the t:slim X2 insulin pump and to help answer any of your questions!
Please note that our team will not have additional information on timelines for the new Tandem t:slim mobile app* release. It will be available in May 2025, and we will notify everyone once it's officially launched.
Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.
The Tandem t:slim Mobile App is an accessory intended for use as a connected software device that is able to reliably and securely communicate with compatible insulin pumps. The Tandem t:slim mobile app is not intended to control an insulin pump and is not intended as a replacement for the information displayed on your insulin pump. Dosing decisions should not be made based on the secondary display device. The user should follow the instructions on the continuous glucose monitoring system and insulin pump. This secondary device is not intended to replace self-monitoring practices as advised by a physician. Tandem Source is a web application intended to support diabetes management through the display and analysis of information uploaded from Tandem insulin pumps. Tandem t:slim X2 insulin pump with Control-IQ provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will adjust insulin delivery according to the predicted glucose when used with a compatible CGM and Tandem t:slim X2 insulin pump with Basal-IQ provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will stop insulin delivery according to the predictive low glucose when used with a compatible CGM. Dexcom CGM is a continuous glucose monitoring system indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated.
*Bolus delivery from the Tandem t:slim mobile app requires a compatible smartphone model and operating system, software version 7.8.1 onwards on the t:slim X2 insulin pump and additional training. † Dexcom G7 CGM sold separately. Funded Dexcom CGM is available through Pharmac for eligible individuals, for more information visit https://pharmac.govt.nz/. ‡ If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations use a blood glucose meter to make diabetes treatment decisions. # Between the hours of 4 am to 7 am while using Control‑IQ technology. § As measured by Dexcom CGM. || Dexcom G7 and ONE+ are our Dexcom’s accurate CGM systems as compared to Dexcom G6. Control-IQ technology is not a substitute for active self-management of your diabetes. ¶ Control-IQ technology is only available with Dexcom G6 or G7 CGM. ^ Smart device sold separately. To view a list of compatible devices, visit nzmsdiabetes.co.nz/mobile-compatibility. ** Visit pharmac.govt.nz for more information. †† Uploads to the Tandem Source platform do not take place in real- time and should not be relied upon by healthcare providers, pump users, or caregivers for remote patient monitoring.
1. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. 2018;41(10):2155-2161. doi:10.2337/dc18-0771. 2. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097. 3. Data on File. 4. Welsh JB, et al. Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems.
New Zealand Medical & Scientific Limited, a Dexcom company, 2a Fisher Crescent, Mt Wellington, Auckland, 1060.